Find syndicated market insights and custom brand analyses through our services offered in the nephrology market. Spherix’s independent research is conducted by our intelligence teams in collaboration with our proprietary network of nephrologists, patients, and leading KOLs.
From: FiercePharma By: Beth Snyder Bulik The lupus nephritis category is sporting a first-ever brand battle—two new-to-category drugs with...
After several months on the market to treat lupus nephritis, uptake and prescribing patterns of Benlysta and Lupkynis reveal nephrologists...
According to new research from Spherix Global Insights, the FDA approval of Farxiga is likely to ignite a shift towards...
Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains...
